Source: Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Pei-Chun Chan, Pin-Hui Lee, Min-Ju Lu, You-Chieh Huang, Teng-Yi Feng, Wen-Wen Chen, Chia-Chi Lee, Yen-Fang Huang, Chen-Yuan Chiang. Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly. Eur Respir J, 53 (3) 1802396; 10.1183/13993003.02396-2018

Member's Comments

No comment yet.

Related content which might interest you: Outcomes of treatment of latent tuberculosis infection in children with two different regimens Source: Eur Respir J 2006; 28: Suppl. 50, 487s Year: 2006 Comparison of compliance of two therapeutic regimens in treatment of latent tuberculosis infection in Belgrade children Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004 Efficiency of treatment regimens for chronic tuberculosis patients Source: Eur Respir J 2003; 22: Suppl. 45, 519s Year: 2003 Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007 Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population Source: Eur Respir J 2005; 26: Suppl. 49, 624s Year: 2005 Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study Source: Eur Respir J, 52 (6) 1801470; 10.1183/13993003.01470-2018 Year: 2018 Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Bedaquiline in the treatment of patients with co-infection HIV/tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018 Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601799; DOI: 10.1183/13993003.01799-2016 Year: 2017 Long-term results of treatment with bedaquiline in patients with drug-resistant tuberculosis Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007 The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001 A choice of regimen improves completion for patients with latent TB infection Source: Breathe 2008; 4: 366 Year: 2008 The relapses of tuberculosis with multiple drug resistance among patients treated under DOTS-Plus regimen Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Efficacy of linezolide-free chemotherapy schemes in patients with highly drug-resistant tuberculosis Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021 Efficacy of a standard chemotherapy regimen in the management of sputum-positive pulmonary TB relapses Source: Eur Respir J 2003; 22: Suppl. 45, 41s Year: 2003